Envista Holdings Corp. NVST

TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the “TCW Relative Value Mid Cap Fund”. The letter can be downloaded here. Equities advanced in Q2 2026, with the S&P 500 reaching record highs despite volatility from a Federal Reserve leadership transition and Middle East tensions. Markets rebounded from Q1 lows, […]

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the dental equipment & technology industry, including Envista (NYSE:NVST) and its peers.

Envista Holdings (NVST) is set to present at the 2026 Global Healthcare Conference in New York on September 15, giving investors fresh commentary to weigh against recent share performance and fundamentals. Envista Holdings enters the conference with mixed momentum, with the share price up 8.02% year to date but a 30 day share price return down 13.86%, and longer term total shareholder returns of 12.16% over one year and a decline of 44.86% over five years. Compare Envista Holdings with a...

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that the company will participate in the Baird 2026 Global Healthcare Conference. The fireside chat will take place on Tuesday, September 15, 2026, from 9:40 – 10:10 AM ET.

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.

Envista Holdings Corp. (NYSE:NVST) shares rose 2.

Markets wobble heading into the Labor Day weekend as bond vigilantes push back against Washington, oil stays tense with Middle East strikes escalating, and Wall Street analysts make bold calls on names ranging from Broadcom to Moderna that could reshape your portfolio positioning.

Envista Holdings arrives at a tricky valuation point for investors, with an intrinsic value estimate from a Discounted Cash Flow (DCF) suggesting the stock may trade below its underlying cash flow value, while market based multiples make the shares look more expensive and the broader checklist does not flag a clear bargain. Over the past 5 years the stock has fallen 38.0%, which leaves long term holders with a weak result and puts extra focus on whether the current price reflects realistic...